Evaluating the efficacy and safety of the myrtle (Myrtus communis) in treatment and prognosis of patients suspected to novel coronavirus disease (COVID-19): study protocol for a randomized controlled trial

Abstract Background Since December 2019, the outbreak of coronavirus pneumonia was observed in China and quickly propagate in all of the world. Nowadays, many trials are underway on this disease in which the efficacy of various therapeutic remedies including chemical or natural agents as well as dif...

Full description

Bibliographic Details
Main Authors: Maryam Azimi, Fatemeh Sadat Hasheminasab
Format: Article
Language:English
Published: BMC 2020-11-01
Series:Trials
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13063-020-04915-w
id doaj-193e38261fe4422f8a8299940aec54ff
record_format Article
spelling doaj-193e38261fe4422f8a8299940aec54ff2020-11-26T12:52:02ZengBMCTrials1745-62152020-11-012111510.1186/s13063-020-04915-wEvaluating the efficacy and safety of the myrtle (Myrtus communis) in treatment and prognosis of patients suspected to novel coronavirus disease (COVID-19): study protocol for a randomized controlled trialMaryam Azimi0Fatemeh Sadat Hasheminasab1Gastroenterology and Hepatology Research Center, Kerman University of Medical SciencesPharmacology Research Center, Zahedan University of Medical Sciences (ZaUMS)Abstract Background Since December 2019, the outbreak of coronavirus pneumonia was observed in China and quickly propagate in all of the world. Nowadays, many trials are underway on this disease in which the efficacy of various therapeutic remedies including chemical or natural agents as well as different non-pharmacological methods such as acupuncture are evaluated. This study aims at investigating the effect of M. communis fruit for treatment of COVID-19 disease. Methods We are performing an open-label randomized controlled trial on outpatients clinically suspected to COVID-19 disease in the age range of 18–65 years old with mild to moderate symptoms and without respiratory distress. Patients in both groups (M. communis and control) receive conventional therapy, but those in M. communis group get M. communis preparation in addition to conventional therapy. Intervention will continue for 5 days and the study outcomes including clinical status as well as mortality rate and adverse effects will be measured up to 14 days. Discussion The protocol describes the design of an ongoing randomized controlled trial to establish the evidence for the usage of water extract of M. communis fruit in clinically suspected COVID-19 disease and identify any safety concerns. Trial registration The trial has been registered at the Iranian Registry of Clinical Trials website under the code IRCT20180923041093N3 on March 28th, 2020 ( https://www.irct.ir/trial/46721 ). The results will be disseminated through manuscript publications and presentations to scientific meetings.http://link.springer.com/article/10.1186/s13063-020-04915-wCOVID-19MyrtleHerbPersian medicineM. communis
collection DOAJ
language English
format Article
sources DOAJ
author Maryam Azimi
Fatemeh Sadat Hasheminasab
spellingShingle Maryam Azimi
Fatemeh Sadat Hasheminasab
Evaluating the efficacy and safety of the myrtle (Myrtus communis) in treatment and prognosis of patients suspected to novel coronavirus disease (COVID-19): study protocol for a randomized controlled trial
Trials
COVID-19
Myrtle
Herb
Persian medicine
M. communis
author_facet Maryam Azimi
Fatemeh Sadat Hasheminasab
author_sort Maryam Azimi
title Evaluating the efficacy and safety of the myrtle (Myrtus communis) in treatment and prognosis of patients suspected to novel coronavirus disease (COVID-19): study protocol for a randomized controlled trial
title_short Evaluating the efficacy and safety of the myrtle (Myrtus communis) in treatment and prognosis of patients suspected to novel coronavirus disease (COVID-19): study protocol for a randomized controlled trial
title_full Evaluating the efficacy and safety of the myrtle (Myrtus communis) in treatment and prognosis of patients suspected to novel coronavirus disease (COVID-19): study protocol for a randomized controlled trial
title_fullStr Evaluating the efficacy and safety of the myrtle (Myrtus communis) in treatment and prognosis of patients suspected to novel coronavirus disease (COVID-19): study protocol for a randomized controlled trial
title_full_unstemmed Evaluating the efficacy and safety of the myrtle (Myrtus communis) in treatment and prognosis of patients suspected to novel coronavirus disease (COVID-19): study protocol for a randomized controlled trial
title_sort evaluating the efficacy and safety of the myrtle (myrtus communis) in treatment and prognosis of patients suspected to novel coronavirus disease (covid-19): study protocol for a randomized controlled trial
publisher BMC
series Trials
issn 1745-6215
publishDate 2020-11-01
description Abstract Background Since December 2019, the outbreak of coronavirus pneumonia was observed in China and quickly propagate in all of the world. Nowadays, many trials are underway on this disease in which the efficacy of various therapeutic remedies including chemical or natural agents as well as different non-pharmacological methods such as acupuncture are evaluated. This study aims at investigating the effect of M. communis fruit for treatment of COVID-19 disease. Methods We are performing an open-label randomized controlled trial on outpatients clinically suspected to COVID-19 disease in the age range of 18–65 years old with mild to moderate symptoms and without respiratory distress. Patients in both groups (M. communis and control) receive conventional therapy, but those in M. communis group get M. communis preparation in addition to conventional therapy. Intervention will continue for 5 days and the study outcomes including clinical status as well as mortality rate and adverse effects will be measured up to 14 days. Discussion The protocol describes the design of an ongoing randomized controlled trial to establish the evidence for the usage of water extract of M. communis fruit in clinically suspected COVID-19 disease and identify any safety concerns. Trial registration The trial has been registered at the Iranian Registry of Clinical Trials website under the code IRCT20180923041093N3 on March 28th, 2020 ( https://www.irct.ir/trial/46721 ). The results will be disseminated through manuscript publications and presentations to scientific meetings.
topic COVID-19
Myrtle
Herb
Persian medicine
M. communis
url http://link.springer.com/article/10.1186/s13063-020-04915-w
work_keys_str_mv AT maryamazimi evaluatingtheefficacyandsafetyofthemyrtlemyrtuscommunisintreatmentandprognosisofpatientssuspectedtonovelcoronavirusdiseasecovid19studyprotocolforarandomizedcontrolledtrial
AT fatemehsadathasheminasab evaluatingtheefficacyandsafetyofthemyrtlemyrtuscommunisintreatmentandprognosisofpatientssuspectedtonovelcoronavirusdiseasecovid19studyprotocolforarandomizedcontrolledtrial
_version_ 1724414540012060672